BI
Last reporting period 30 Jun, 2024
Updated 19 Sep, 2024
Last price
—
Market cap $B
28.872
Exchange
XNAS - Nasdaq
1.9 B
Last period Cash and equivalents ,USD
-35%
Cash and equivalents has decreased in 5 years
What is Cash and equivalents ?
Cash is the amount of free cash on the company's accounts, as well as short-term liquid investments.
See also Biogen
Company Analysis
BIIB valuation, rating, competitors, insights and company profile
Eyestock Rating
BIIB financial analysis by Eyestock methodology
Valuation
BIIB valuation using historical relative method
Statements
BIIB Income Statements, Balance Sheet and Cash Flow Statements
Dividends
BIIB dividend yield and annual dividend
Cash is the amount of free cash on the company's accounts, as well as short-term liquid investments.
Biogen`s Cash and equivalents for the period ended 2024-06-30 are 1.9 B USD
